NICE Single Technology Appraisal Guidance No 256 –
Rivaroxaban for the prevention of stroke and systemic embolism in
people with atrial fibrillation
This NICE guidance was published on 23 May
2012. The web reference for the appraisal and other
related documents is: www.nice.org.uk/TA256
NHSScotland should note
that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (756/12) on
this medication for this indication in 13 February 2012. This
stated that:
rivaroxaban (Xarelto®) is
accepted for restricted use within NHS Scotland for the prevention
of stroke and systemic embolism in adult patients with non-valvular
atrial fibrillation with one or more risk factors, such as
congestive heart failure, hypertension, age ≥ 75 years, diabetes
mellitus, prior stroke or transient ischaemic attack.
SMC restriction: Rivaroxaban
is accepted for use in patients who have poor INR control despite
evidence that they are complying with a coumarin anticoagulant and
in patients who are allergic to or unable to tolerate coumarin
anticoagulants.
Access the advice of SMC
3. There is no material difference between the
recommendations of the NICE STA and SMC.
If you need further assistance, please contact
Eleanor Brownlee in
the first instance. Tel 0141 225 6873
Published Date: 23 May 2012
